As more pressures are exerted upon the cold chain in the form of globalisation, high priced investments and regulatory demands, focus has zoomed in on cost efficiency and obtaining the most streamlined but secure route to the patient. Lean management principles are known to be able to reduce costs and improve customer service within the cold chain and are as key criteria for any 3PL within the market.
The first quarter of 2016 hosted plenty of activity from the pharma and cold chain industries. This was seen in the form of patent challenges, landmark agreements, extreme market reactions as well as a nationwide medicine ban for hundreds of products. Read on for this quarter’s highlights from Cold Chain IQ & Pharma IQ.
China’s cold chain has been dubbed as ‘one of the hottest sub-industries of logistics’, with temperature controlled logistics set to develop as an attractive area of interest for investors. (3)
Global Cold Chain Alliance has noted that the Cold Chain is positioned to take full advantage of solar energy and is even starting to emerge as a key player in this space.
Research has noted that pollution from transport refrigeration unit vehicles could hand EU members a bill of around €22 billion over the next 10 years. With the size of the refrigeration fleet also on the rise.
Last month saw Johnson & Johnson win the Best Temperature Controlled Logistics Project Award at the 2016 Temperature Controlled Logistics Awards. This was in relation to organising the supply chain through Sierra Leone for the shipment and storage of an Ebola vaccine.
When it comes to integrating the pharma cold-chain, technology is invariably seen as having a big part to play. However, it can also form a big part of the problem. Here Alan Kennedy examines the virtues and limitations of technology when it comes to collaborative solutions.
At the recent MHRA GDP & GMP Symposium Martine Powell, GMDP inspector examined the known future for GMP compliance.
According to statistics from the "Active Pharmaceutical Ingredient Market - Global Forecast to 2020" the global active pharmaceutical ingredient market is expected to climb to US$205.51 billion by 2020.
The number of Phase Ib studies are on the rise as it presents an opportunity to test the drug’s possible effectiveness before launching into a larger and riskier Phase II trial. Clinicaltrials.gov recorded 89 Phase I studies in 2010 globally, with a dramatic increase of 1825 trials in just 4 years. More parties are involved in the conduct of a Phase Ib study, as opposed to a Phase I study, as it includes the Phase I unit, CRO and referring si